Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists.

MLA

Kym, Philip R., et al. “Screening for Cardiovascular Safety: A Structure-Activity Approach for Guiding Lead Selection of Melanin Concentrating Hormone Receptor 1 Antagonists.” Journal of Medicinal Chemistry, vol. 49, no. 7, Apr. 2006, pp. 2339–52. EBSCOhost, https://doi.org/10.1021/jm0512286.

APA

Kym, P. R., Souers, A. J., Campbell, T. J., Lynch, J. K., Judd, A. S., Iyengar, R., Vasudevan, A., Gao, J., Freeman, J. C., Wodka, D., Mulhern, M., Zhao, G., Wagaw, S. H., Napier, J. J., Brodjian, S., Dayton, B. D., Reilly, R. M., Segreti, J. A., Fryer, R. M., … Polakowski, J. S. (2006). Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists. Journal of Medicinal Chemistry, 49(7), 2339–2352. https://doi.org/10.1021/jm0512286

Chicago

Kym, Philip R, Andrew J Souers, Thomas J Campbell, John K Lynch, Andrew S Judd, Rajesh Iyengar, Anil Vasudevan, et al. 2006. “Screening for Cardiovascular Safety: A Structure-Activity Approach for Guiding Lead Selection of Melanin Concentrating Hormone Receptor 1 Antagonists.” Journal of Medicinal Chemistry 49 (7): 2339–52. doi:10.1021/jm0512286.